Hypothalamic obesity
Information
- Disease name
- Hypothalamic obesity
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04725240 | Completed | Phase 2 | Open-Label Study of Setmelanotide in Hypothalamic Obesity | June 7, 2021 | June 28, 2022 |
| NCT00892073 | Completed | Phase 2 | Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy | May 2006 | January 2008 |
| NCT01061775 | Completed | Phase 1/Phase 2 | Effects of Exenatide on Hypothalamic Obesity | January 2010 | March 15, 2019 |
| NCT00171613 | Completed | Phase 4 | A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients | February 2005 | |
| NCT02664441 | Completed | Phase 3 | Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity | March 2016 | July 31, 2020 |
| NCT02849743 | Completed | Phase 2 | Intranasal Oxytocin in Hypothalamic Obesity | October 2016 | May 2022 |
| NCT02860923 | Completed | Phase 3 | Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy | January 11, 2017 | September 30, 2018 |
| NCT03673813 | Completed | A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity | June 29, 2016 | July 1, 2018 | |
| NCT05319301 | Completed | N/A | Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study) | April 1, 2022 | November 1, 2023 |
| NCT05774756 | Enrolling by invitation | Phase 3 | A Trial of Setmelanotide in Acquired Hypothalamic Obesity | April 26, 2023 | April 16, 2025 |
| NCT06299891 | Not yet recruiting | Phase 2 | Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity | May 1, 2024 | May 31, 2026 |
| NCT06046443 | Not yet recruiting | Phase 2 | A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | June 17, 2024 | January 31, 2026 |
| NCT06217848 | Recruiting | Early Phase 1 | The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study | November 28, 2022 | March 8, 2024 |
| NCT06239116 | Recruiting | Phase 1 | A Study of RM-718 in Healthy Subjects and in Patients With HO | March 5, 2024 | June 30, 2025 |
| NCT01783717 | Unknown status | N/A | Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage | December 2012 | July 2015 |
| NCT03708913 | Withdrawn | N/A | Neuromodulation for Hypothalamic Obesity | June 1, 2019 | April 1, 2020 |
| NCT05147415 | Withdrawn | Phase 2 | Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) | November 11, 2021 | December 9, 2022 |